Neuropathic Pain - UCB's Vimpat set to compete with major players

The neuropathic pain market is forecast to almost triple to over $6.3 billion by the end of the forecast period in 2017. The growth in the market is spurred on by the uptake of Pfizer's Lyrica (pregabalin), forecast to reach almost $3 billion in sales by 2017. Vimpat is the most promising pipeline drug, forecast to take some $480m by 2017.

UCB's Vimpat (lacosamide) demonstrates the most potential in the pipeline and is well suited to compete in this market. Datamonitor has forecast Vimpat to generate over $480m, over a third of the total pipeline sales by 2017.

Neuropathic pain offers diverse market opportunities, with niche underserved neuropathic pain indications (e.g. HIV associated neuropathic pain) offering a good market entry point.

Following the recent negative FDA advice on Cephalon's Fentora, Datamonitor has forecast that the drug will not launch for neuropathic pain. This is a blow to the development of a niche breakthrough neuropathic pain market.

Read more...

• Therapeutic Vaccines (17/08/2010)
• Type 1 Diabetes (28/06/2010)
• Parkinson’s Disease (28/06/2010)

• Non-hormonal Treatments for Menopausal Symptoms (10/10/2008)
• Rx-to-OTC Strategies (10/10/2008)
• Asthma (10/10/2008)
• Vaccines for Adults and the Elderly (10/10/2008)
• Fibromyalgia (10/10/2008)
• Novel Therapeutic Approaches in Cardiovascular Medicine (09/10/2008)
• Diagnostics in Neurology (09/10/2008)
• Optimizing Brand Lifecycle Management (09/10/2008)
• Cytotoxic Therapy Cancer Brands (09/10/2008)

---